Home >> Research Area >>Others>>Thrombopoietin Receptor>> Eltrombopag Olamine

Eltrombopag Olamine

C-mpl agonist CAS# 496775-62-3

Eltrombopag Olamine

Catalog No. BCC1549----Order now to get a substantial discount!

Product Name & Size Price Stock
Eltrombopag Olamine: 5mg $58 In Stock
Eltrombopag Olamine: 10mg Please Inquire In Stock
Eltrombopag Olamine: 20mg Please Inquire Please Inquire
Eltrombopag Olamine: 50mg Please Inquire Please Inquire
Eltrombopag Olamine: 100mg Please Inquire Please Inquire
Eltrombopag Olamine: 200mg Please Inquire Please Inquire
Eltrombopag Olamine: 500mg Please Inquire Please Inquire
Eltrombopag Olamine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Eltrombopag Olamine

Number of papers citing our products

Chemical structure

Eltrombopag Olamine

3D structure

Chemical Properties of Eltrombopag Olamine

Cas No. 496775-62-3 SDF Download SDF
PubChem ID 9915926 Appearance Powder
Formula C29H36N6O6 M.Wt 564.63
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Eltrombopag diethanolamine salt; SB-497115GR
Solubility DMSO : ≥ 50 mg/mL (88.55 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name 2-aminoethanol;3-[(5E)-5-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]hydrazinylidene]-6-oxocyclohexa-1,3-dien-1-yl]benzoic acid
SMILES CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)NN=C3C=CC=C(C3=O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N
Standard InChIKey TYYXAUPVEKKAFG-HTQZHWFGSA-N
Standard InChI InChI=1S/C25H22N4O4.2C2H7NO/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33;2*3-1-2-4/h4-13,27-28H,1-3H3,(H,32,33);2*4H,1-3H2/b26-21+;;
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Eltrombopag Olamine

DescriptionEltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) [1] Target: thrombopoietin-receptor (c-mpl) Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. in vitro: Eltrombopag demonstrated a half maximal effective concentration (EC50) of 0.27 uM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR (BAF3/IRF-1/hTpoR) [1]. Eltrombopag stimulates the growth of TPO-dependent cell lines via JAK2 and STAT signaling pathways and stimulates isolated human CD34+ cells to become megakaryocytes and produce platelets [2]. in vivo: Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the placebo group [3]. Eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. The pharmacokinetics of eltrombopag was dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner [4]. Toxicity: There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication [4]. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts in the desired range [5]. Clinical trial: Eltrombopag In Cord Blood Or Haploidentical Bone Marrow Transplantation. Phase 2

References:
[1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30. [2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93. [3]. McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007 Nov 29;357(22):2227-36. [4]. Jenkins JM, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007 Jun 1;109(11):4739-41. [5]. Saleh MN, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.

Eltrombopag Olamine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Eltrombopag Olamine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Eltrombopag Olamine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7711 mL 8.8554 mL 17.7107 mL 35.4214 mL 44.2768 mL
5 mM 0.3542 mL 1.7711 mL 3.5421 mL 7.0843 mL 8.8554 mL
10 mM 0.1771 mL 0.8855 mL 1.7711 mL 3.5421 mL 4.4277 mL
50 mM 0.0354 mL 0.1771 mL 0.3542 mL 0.7084 mL 0.8855 mL
100 mM 0.0177 mL 0.0886 mL 0.1771 mL 0.3542 mL 0.4428 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Eltrombopag Olamine

Description: IC50 Value: 0.27 uM (EC50 in murine BAF3 cells) [1] Eltrombopag is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. Potential advantages of eltrombopag may include a sustained platelet response and a good tolerability profile. in vitro: Eltrombopag demonstrated a half maximal effective concentration (EC50) of 0.27 uM in murine BAF3 cells transfected with the luciferase reporter gene under direction of the STAT-activated IRF-1 promoter and human TpoR (BAF3/IRF-1/hTpoR) [1]. Eltrombopag stimulates the growth of TPO-dependent cell lines via JAK2 and STAT signaling pathways and stimulates isolated human CD34+ cells to become megakaryocytes and produce platelets [2]. in vivo: Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the placebo group [3]. Eltrombopag was administered as once-daily oral capsules for 10 days at doses of 5, 10, 25, 30, 50, and 75 mg. The pharmacokinetics of eltrombopag was dose dependent and linear, and eltrombopag increased platelet counts in a dose-dependent manner [4]. Toxicity: There were no apparent differences in the incidence or severity of adverse events in subjects receiving active or placebo study medication [4]. Long-term treatment with eltrombopag was generally safe, well tolerated, and effective in maintaining platelet counts in the desired range [5]. Clinical trial: Eltrombopag In Cord Blood Or Haploidentical Bone Marrow Transplantation. Phase 2

Featured Products
New Products
 

Description

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is a thrombopoietin-receptor agonist used to treat low blood platelet counts with chronic immune thrombocytopenia.

Keywords:

Eltrombopag Olamine,496775-62-3,Eltrombopag diethanolamine salt; SB-497115GR,Natural Products,Thrombopoietin Receptor, buy Eltrombopag Olamine , Eltrombopag Olamine supplier , purchase Eltrombopag Olamine , Eltrombopag Olamine cost , Eltrombopag Olamine manufacturer , order Eltrombopag Olamine , high purity Eltrombopag Olamine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: